Summary
Boston Scientific Corporation reported strong financial results for the first quarter of 2021, with a significant increase in net sales and a substantial rebound in net income compared to the same period in 2020. Net sales grew by 8.2% to $2.752 billion, driven by an 5.6% operational growth and the positive impact of foreign currency fluctuations. This growth was observed across most of its key business segments, indicating a recovery from pandemic-related impacts and successful integration of recent acquisitions. The company achieved a net income available to common stockholders of $327 million, or $0.23 per diluted share, a marked improvement from $11 million ($0.01 per diluted share) in Q1 2020. Excluding certain non-GAAP adjustments, adjusted net income available to common stockholders was $524 million, or $0.37 per diluted share, reflecting the underlying strength of the business. The company also successfully completed the divestiture of its Specialty Pharmaceuticals business and made strategic acquisitions, notably Preventice Solutions, Inc., which contributed to the growth in its Cardiac Rhythm Management segment. Boston Scientific maintained a solid financial position with $2.016 billion in cash and cash equivalents and $2.708 billion in working capital as of March 31, 2021. The company is navigating the ongoing COVID-19 pandemic, noting some regions experienced renewed restrictions, but remains optimistic about its long-term fundamentals and ability to manage through challenges.
Financial Highlights
49 data points| Revenue | $2.75B |
| Cost of Revenue | $894.00M |
| Gross Profit | $1.86B |
| SG&A Expenses | $1.02B |
| Operating Expenses | $1.49B |
| Operating Income | $370.00M |
| Interest Expense | $82.00M |
| Net Income | $341.00M |
| EPS (Basic) | $0.23 |
| EPS (Diluted) | $0.23 |
| Shares Outstanding (Basic) | 1.42B |
| Shares Outstanding (Diluted) | 1.43B |
Key Highlights
- 1Net sales increased by 8.2% to $2.752 billion in Q1 2021, up from $2.543 billion in Q1 2020, driven by operational growth and favorable currency movements.
- 2Net income available to common stockholders rose significantly to $327 million ($0.23 per diluted share) in Q1 2021, from $11 million ($0.01 per diluted share) in Q1 2020.
- 3Adjusted net income available to common stockholders (a non-GAAP measure) was $524 million ($0.37 per diluted share) for Q1 2021, demonstrating robust underlying performance.
- 4Completed the divestiture of the Specialty Pharmaceuticals business on March 1, 2021, for approximately $800 million.
- 5Acquired Preventice Solutions, Inc. on March 1, 2021, for an upfront payment of $925 million, adding mobile cardiac health solutions to its portfolio.
- 6Gross profit margin slightly decreased to 67.5% from 68.3% year-over-year, primarily due to unfavorable product mix and pricing pressures, partially offset by manufacturing cost reductions.
- 7The company ended the quarter with $2.016 billion in cash and cash equivalents and maintained compliance with its financial covenants.